BiPar Sciences Expands Clinical Development Of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial In Uterine Cancer
BiPar Sciences, Inc. announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company’s DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.
More: continued here
Filed under: Clinical Trials on June 1st, 2008